North America Anti-Obesity Drugs Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The North America Anti-Obesity Drugs Market size is expected to reach US$ 147,317.2 Million by 2031 from US$ 12,583.7 Million in 2024. The market is estimated to record a CAGR of 34.5% from 2025 to 2031.

Executive Summary and North America Anti-Obesity Drugs Market Analysis:

The North America anti-obesity drugs market is divided into the US, Canada, and Mexico. North America is likely to capture a significant share of the global market. The growth in North America is characterized by rising obesity rates, increasing health awareness, and advancements in pharmaceutical research. The region faces a high prevalence of obesity due to sedentary lifestyles, unhealthy dietary habits, and genetic factors, prompting greater demand for effective weight management solutions. Governments and healthcare organizations are also promoting obesity prevention and treatment initiatives, further boosting market expansion. Additionally, improved access to healthcare and insurance coverage for obesity treatments encourages patient adoption of these medications. Technological innovations and the development of more effective, safer drugs-such as GLP-1 receptor agonists-have significantly enhanced treatment outcomes, gaining trust among healthcare providers and patients alike. Furthermore, growing investment by pharmaceutical companies in R&D and strategic partnerships for drug development and marketing contributes to the market's rapid growth. These combined factors position North America as a leading region in the global anti-obesity drug market.

North America Anti-Obesity Drugs Market: Strategic Insights

North America Anti-Obesity Drugs Market Segmentation Analysis:

• By Type, the North America Anti-Obesity Drugs Market is segmented into Prescription Drugs and OTC Drugs. Prescription Drugs held the largest share of the market in 2024.
• By Mechanism of Action, the North America Anti-Obesity Drugs Market is segmented into Centrally Acting Drugs, Peripherally Acting Drugs, and Others. Centrally Acting Drugs held the largest share of the market in 2024.
• By Drug Class, the North America Anti-Obesity Drugs Market is segmented into GLP-1 Agonist, Lipase Inhibitors, MC4R agonist, and Others. GLP-1 Agonist held the largest share of the market in 2024.
• By GLP-1 agonist, the North America Anti-Obesity Drugs Market is segmented into Semaglutide, Liraglutide, and Tirzepatide (Zepbound). Semaglutide held the largest share of the market in 2024.
• By Application, the North America Anti-Obesity Drugs Market is segmented into Appetite Suppression, Inhibition of Fat Absorption or Digestive Enzymes, Metabolic Enhancement, and Combination. Appetite Suppression held the largest share of the market in 2024.
• By Route of Administration, the North America Anti-Obesity Drugs Market is segmented into Oral and Parenteral. Parenteral held the largest share of the market in 2024.
• By Distribution Channel, the North America Anti-Obesity Drugs Market is segmented into Hospital Pharmacies, Online Channel, and Retail Pharmacies. Hospital Pharmacies held the largest share of the market in 2024.

North America Anti-Obesity Drugs Market Players Density: Understanding Its Impact on Business Dynamics

The North America Anti-Obesity Drugs Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

North America Anti-Obesity Drugs Market Outlook

The mounting prevalence of obesity worldwide is a primary driver for the global anti-obesity drugs market. As obesity rates rise due to sedentary lifestyles, poor diets, and genetic factors, there is an increasing demand for effective medical interventions. This growing health concern pushes patients and healthcare providers to seek pharmacological solutions alongside lifestyle changes. Consequently, pharmaceutical companies are investing more in developing and marketing anti-obesity drugs. Overall, the surge in obesity cases significantly fuels market growth and innovation in this sector. According to the World Health Organization (WHO), the global prevalence of obesity more than doubled between 1990 and 2022. In 2022, 2.5 billion adults aged 18 and older were overweight, with over 890 million classified as obese: this equates to 43% of adults (43% of men and 44% of women), up from 25% in 1990. Overweight prevalence varied by region, with rates as low as 31% in the WHO South-East Asia and African Regions, and reaching up to 67% in the Region of the Americas.

According to the report published by the World Obesity Atlas, the prevalence of obesity is projected to increase from 14% in 2023 to 24% by 2035, affecting nearly 2 billion individuals. The number of overweight and obese people is expected to increase from 2.6 billion in 2020 to over 4 billion by 2035, up from over, marking a rise from 38% to over 50% of the world's population, excluding children under five. The increasing obesity prevalence has resulted in a large patient population suffering from chronic conditions that severely impact daily functioning and have significant implications for mortality. Anti-obesity drugs, also known as weight loss drugs, include various pharmaceutical treatments aimed at helping individuals manage obesity and related health conditions. These medications work by influencing appetite regulation, fat absorption, and metabolism. They can improve weight loss outcomes, especially for patients with obesity-related health issues, while enhancing quality of life.

Reducing obesity rates could alleviate the economic burden associated with the disease. According to the World Obesity Atlas, the total costs related to obesity-including healthcare and economic productivity losses-are expected to exceed US$ 4 trillion by 2035, accounting for approximately 3% of global GDP from US$1.96 trillion in 2020. The rising prevalence of obesity is creating a significant demand for effective treatments, making the global anti-obesity drugs market increasingly vital. As more individuals suffer from obesity-related chronic conditions, pharmaceutical solutions play a crucial role in managing health outcomes and improving quality of life. The growth in patient numbers drives innovation and investment in this market, aiming to provide safer and more effective therapies. Additionally, reducing obesity through these medical interventions can help lessen the substantial economic burden on healthcare systems and societies. Overall, the continued rise in obesity underscores the importance and potential growth of the anti-obesity drugs sector worldwide.

North America Anti-Obesity Drugs Market Country Insights

By country, the North America Anti-Obesity Drugs Market is segmented into the United States, Canada, and Mexico. The United States held the largest share in 2024.

According to the data from the National Health and Nutrition Examination Survey, the prevalence of obesity in adults was 40.3% in the country during August 2021-August 2023. Obesity occurrence was higher in adults aged 40-59 (46.4%) than in people aged 20-39 (35.5%) and 60 and older (38.9%). This surge in obesity rates has led to an increase in related comorbidities such as type 2 diabetes, hypertension, and cardiovascular diseases, escalating healthcare costs. Thus, there is a growing demand for effective anti-obesity medications to mitigate these health risks.

Key pharmaceutical companies have introduced innovative treatments that have reshaped the market landscape. Novo Nordisk's semaglutide-based drugs, Ozempic and Wegovy, have become widely prescribed for type 2 diabetes and obesity management, respectively. Per the Drug Usage Statistics, United States, 2013 - 2022, provided by the ClinCalc DrugStats Database, semaglutide was the 48th most commonly prescribed medication in the US in 2022, with more than 13 million prescriptions. Furthermore, these medications aid in weight reduction and improve management of obesity-related comorbidities, thereby enhancing their appeal among healthcare providers and patients. Eli Lilly has also made significant strides with its GLP-1 receptor agonist, tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss. In 2024, Eli Lilly's stock soared 16% following promising results from a Phase 3 trial of its new oral weight-loss drug, orforglipron, which demonstrated an average weight loss of 16 pounds over 40 weeks.

North America Anti-Obesity Drugs Market Company Profiles

Some of the key players operating in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk AS, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC., AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

North America Anti-Obesity Drugs Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise